Active clinical trials for "Diabetic Foot"

The purpose of this study is to determine whether using the OWEMR as part of the standard of care for Diabetic Foot Ulcers reduces the rate of lower limb amputations and to quantify the relationship between glycemic control and the rate of amputation secondary to chronic foot ulcers in Type II Diabetes.

To evaluate the effectiveness of PriMatrix in the treatment of DFUs in subjects without significantly compromised arterial circulation.

The objective of this project is to assess the fidelity and sustainability of in improving provider performance with Ankle Brachial Index (ABI) assessment and ulcer staging with the would ischemia foot infection (WIfI) tool for new patients with lower extremity ulcers due to peripheral artery disease (PAD) and diabetes mellitus (DM) at RHCs in the telemedicine network through a rural provider education program that is aligned with preexisting continuing medical education activities.

The TELEPIED project aims to show that it is possible to reduce the number of hospitalization days of a patient with ulcers of the foot thanks to a new organization of care, based on the intervention of a coordinating nurse interacting with the nurse in charge of the patient thanks to a telemedicine tool allowing the transfer of photos and ensuring itself a regular follow-up of the evolution of the wound and adapting the support nurse to the home if necessary. It is a monocenter, randomized, in parallel study, in 180 diabetic patients with ulcers of the foot. Patients included in the conventional group will be followed according to the usual practice Patients included in the "telepied" group will benefit from a personalized accompaniment by a nurse referring to diabetic foot ulcers who will guide and advise the nurse at home by acting by delegating tasks of the investigator. The patient will be visited by the referring nurse every 15 days. During these visits, the referring nurse will have the objective to evaluate the evolution of the ulcer as well as the care performed. This visit also allows a close personalized accompaniment for the patient, who will benefit from an education adapted to the characteristics of ulcer (discharge modalities for example ..) and its way of life. Every patients will be followed for one year (12 months).

This will be a continuing, prospective study of diabetic foot ulcers and infections, risk factors and clinical outcomes and a limited data set conducted by the investigator through the establishment of a data and tissue repository in the uT Southwestern Department of Plastic Surgery. in addition, subjects consented for this research will be asked about inclusion in a recruitment database to be used in the recruitment of subjects for future research on diabetic foot complications. about 250 patients are seen for diabetic foot ulcers and infections each year.

This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 2 clinical trial (ALLO-ASC-DFU-201) for 23 months.

The goal of this research is to develop better tools for diagnosing illness of the feet and legs of people who have diabetes. Investigators will use thermal videos of the foot to aid in the refinement of a system designed to detect signs of diabetic peripheral neuropathy (DPN). The team of investigators will also look at diabetic eye disease and how it might relate to diabetic foot disease.

The aim of the study is to evaluate the intra- and inter-rater variability of wound measurements using the 3D camera and to compare with standard measurement methods (2D image method and gel injection). Forty-eight patients with wounds of various sizes are measured by four clinicians. Each wound is measured twice with the 3D camera, once by 2D image method and once by gel injection into wound cavity by two clinicians.

Diabetic patients with a history of diabetic foot are considered to be a high-risk population for increased cardiovascular and all-cause mortality (1,2,3,). Diabetic foot (DF) is responsible for more hospitalizations than any other complication of diabetes and are the leading cause of non-traumatic lower extremity amputations, resulting in nearly 100 000 amputations annually in the US alone (4,5,6). Surgical debridement, as an important component of standard of care of diabetic foot, is intended to remove healing-impaired tissue, decreases bacterial burden, thus to stimulate overall wound closure, while removing as little of healing-competent skin as possible. Furthermore, debrided tissue is often used as a valuable tissue source for research purposes (7,8,9,10). Debrided tissue presents valuable diagnostic and research source to verify pathology, assess prognosis and gain insights into DF molecular pathology, all of which ultimately leads to improved outcomes. We aimed to validate tissue obtained from surgical debridement of DF for the cellular/molecular tissue analyses and biomarkers, to evaluate the pathophysiology of DF and understanding mechanisms that inhibit healing. The age range will be 50-70 years, in order to minimize the effects of irreversible vascular wall changes induced progressively by the aging process. All patients will undergo screening procedures that will include full anamnesis, physical examination, basic laboratory blood tests (full chemistry, CBC); urine examination and EKG will be performed at start and at the end of the study. Patients with a significant myocardial, and renal, cerebrovascular or hepatic disease will be excluded from the study. In a prospective study, we will collect wound edge tissue specimens from 75 patients with DF during surgical debridement. From each patient, 1-4 specimens will be obtained per debridement. To evaluate debrided tissue, each specimen will be processed for paraffin embedding and stained with haematoxylin and eosin. Histopathology analysis of multiple specimens acquired from the same wound will be analysed.

The purpose of the study is to evaluate the effectiveness of a nurse led intervention for high risk patients with diabetic foot ulceration and/or amputation. The effectiveness is defined in two ways 1) as a reduction in complication rates (time till ulceration recurrence, new ulcerations, amputation or reamputation) and 2) as a reduction in hospital readmissions for foot-related complication (one year survival probability: failure = readmission for ulceration recurrence, new ulcerations, amputation or re-amputation).